Share on StockTwits
 

Infinity Pharmaceuticals (NASDAQ:INFI) is scheduled to issue its quarterly earnings data on Tuesday, May 6th. Parties that wish to listen to the company’s conference call can do so using this link.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.68) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.87) by $0.19. On average, analysts expect Infinity Pharmaceuticals to post $-3.31 EPS for the current fiscal year and $-2.80 EPS for the next fiscal year.

Shares of Infinity Pharmaceuticals (NASDAQ:INFI) opened at 9.16 on Monday. Infinity Pharmaceuticals has a 52-week low of $8.72 and a 52-week high of $40.51. The stock’s 50-day moving average is $11.26 and its 200-day moving average is $13.04. The company’s market cap is $442.3 million.

Several analysts have recently commented on the stock. Analysts at Wedbush initiated coverage on shares of Infinity Pharmaceuticals in a research note on Monday, March 3rd. They set an “underperform” rating and a $10.00 price target on the stock. On a related note, analysts at Nomura raised their price target on shares of Infinity Pharmaceuticals from $14.00 to $17.00 in a research note on Wednesday, February 26th. Finally, analysts at Jefferies Group raised their price target on shares of Infinity Pharmaceuticals from $13.00 to $15.00 in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $20.63.

Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.

Stay on top of analysts' upgrades and downgrades with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' ratings changes. Register Now.